Nestlé is reformulating some of its food products to cater to consumers using GLP-1 weight-loss drugs. The company's marketing chief, David Rennie, stated that these medications can dull taste buds and reduce appetite, impacting traditional snack and packaged food sales.

Nestlé is actively testing its offerings on consumers to gauge how taste preferences shift with GLP-1 use. This strategic adjustment acknowledges a market trend where people consume less and experience altered palates, posing a challenge to calorie-dense, high-margin snack categories.

The move reflects a broader industry challenge: adapting to evolving consumer habits driven by new pharmaceutical advancements. Companies reliant on impulse purchases and high-calorie indulgence may need to rethink product development and marketing strategies to maintain relevance.